antileishmanial drugs, and recommendations for treatments vary by region 6 as a result.
Since 1980, more than 608,230 cases of AIDS have been registered in Brazil, with an incidence of 17.9/100,000 inhabitants in 2010 7 , and unlike VL, the propagation of HIV transmission to regions with lower urbanization rates and to small and medium-sized cities has been observed 2 . HIV infections increase the risk of developing VL by 100-to 2,320-fold in endemic areas, reduce the likelihood of a therapeutic response and greatly increase the probability of relapse 2 . However, VL promotes the clinical progression of HIV and the development of AIDS-defi ning conditions 8 .
In general, patients with coinfections show very similar clinical features to classical VL 9 , although the usual clinical features associated with VL (prolonged fever, spleen and liver enlargement, wasting and pancytopenia) are not always present, and atypical presentations occur more often in immunocompromised patients. Furthermore, a clinical diagnosis can also be more diffi cult to establish due to other concomitant opportunistic diseases 10 .
Considering that the endemicity of VL in many Brazilian regions is high and that some reports have addressed the clinical features, drug response and outcomes of HIV-related VL 9, [11] [12] [13] , resULTs
MeTHODs
in this study, we aimed to report the results of a comparative study (based on data from the Information System for Notifi able Diseases) on the epidemiology, clinical presentation, drugs used and outcome of both VL and VL/HIV patients in Tocantins, the newest Brazilian state, between 2007 and 2010.
Study design and data collection
A descriptive study of confi rmed cases with VL and VL/HIV infections was conducted between 2007 and 2010 in Tocantins, Brazil. Tocantins is the newest state of the country (created in 1988) and is located in the central part of Northern Brazil. The 2010 census estimated that the state had a population of 1,383,445 inhabitants, distributed over 277,720.520km 2 , and a population density of 4.98 inhabitants per square kilometer; moreover, it comprises 139 municipalities.
The study was based on the data from the Information System for Notifi able Diseases (Sistema de Informação de Agravos de Notifi cação -SINAN). The patients were divided into two groups: the VL group, consisting of patients without HIV infection, and the VL/HIV coinfection group, consisting of patients with VL and HIV (with and without AIDS). An epidemiological description was produced from both groups. However, reports in which the "HIV coinfection", "drug initially administered" and "developments in the case" fi elds were left blank or incomplete were excluded from both groups. In this database, the diagnosis of VL was made by the presence of symptoms, a blood test for confi rmation (immunological methods) and a parasitological diagnosis.
inclusion and exclusion criteria
The study included patients diagnosed with VL due to the presence of amastigotes in bone marrow smears or indirect immunofl uorescence, which were considered positive with results higher than 1:80, and clinical manifestations that included hepatomegaly or splenomegaly, anemia and thrombocytopenia. The study excluded patients undergoing prior treatment with antileishmanial drugs.
The "LV Investigation Form" included an "HIV coinfection" fi eld. Cases were selected for the study using this information. Patients with a confi rmed diagnosis of VL and positive HIV serum tests were included, while those who left the "HIV coinfection" fi eld blank or marked it as negative were excluded. Co-infected patients were diagnosed with HIV by ELISA, and the result was confi rmed by either indirect immunofl uorescence (IIF) or western blot analysis. Associated causes were considered for patients who, regardless of the effi cacy of the treatment, eventually died from cytopenia or thrombocytopenia, and data were discarded in cases where the patient underwent an inadequate treatment course (e.g., someone who should have been treated with amphotericin B because they had cardiovascular involvement but was treated with Glucantime instead), suffered adverse reactions to the medication, such as renal or hepatic insuffi ciency, or developed associated infections such as pneumonia or severe sepsis.
Subjects from 0-65 years of age of either sex were included in the study. Females who were pregnant or lactating were not excluded. Exclusion criteria included forms with insuffi cient information regarding the initial drug used in the treatment, HIV coinfection status and the progression of the case.
data analysis
Data were codified and analyzed using the Statistical Package for the Social Sciences (SPSS for Windows, version 17.0). The variables used for comparative analyses were gender, age, scholarship, clinical manifestations, initial drug use and development of the disease. All variables are presented as numbers and proportions, and age and scholarship are also presented as means and standard deviations (SDs). The indicators were considered to be the following: the lethality of the VL and VL/HIV infections; the mortality rate directly related to VL and linked to other causes in both groups; the relapse rate in each group; and the annual rate of VL/HIV coinfection. Only new cases were used for the analysis, except for the analysis of relapses. The chi-squared test was used to calculate the difference in the nominal variables between the two groups. The differences in the means between the two groups due to age and scholarship were calculated using Student's t-test. A signifi cance level (α) of 0.05 was considered statistically relevant. The variables with signifi cant results were inserted in the stepwise multivariate model to determine the odds ratios (ORs) with 95% confi dence intervals (CIs) for the association between the HIV/VL coinfection. We used HIV positivity as a dependent variable, each factor as an independent variable and age, gender and scholarship as covariates. Alpha was set at p < 0.05. According to SINAN, 1,779 VL patients were registered in Tocantins between 2007 and 2010. Of those, 33 (2.1%) were coinfected with HIV. There were no data for VL/HIV coinfection status, the initial drug used or developments in the case in 210 reports; thus, these patients were excluded from the comparative analysis. During the same period, there were 23 relapses in the VL group and 3 relapses in the VL/HIV group. Among these 26 cases, fi ve were excluded due to the lack of data regarding the initial drug used for treatment and developments in the case. The transmission of VL has gradually spread to various Brazilian regions. It is believed that rural-urban migration, agroindustrial and man-made projects such as dams, irrigation systems and wells as well as deforestation contribute to the dissemination of this disease 14 . In Tocantins, located in northern Brazil, new urban VL cases have been reported since 2000
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. This suggests that environmental changes such as the destruction of the cerrado vegetation, the construction of new cities and the rapid and intense migration of rural populations to urban peripheries could have played a role in the transmission of VL. HIV/AIDS is also endemic in Brazil 15 , and an increase in the number of cases of VL/HIV coinfections has been observed since the early 1990s. The number of cases is projected to increase due to the geographical overlap of the two infections as a result of the urbanization of leishmaniasis and the internalization of HIV infection. In VL-endemic regions, HIV infection increases the risk of developing clinically evident leishmaniasis. Leishmaniasis is endemic to Tocantins and is in the process of expanding both geographically and in magnitude. However, information on coinfection by VL and HIV in the northern region of Brazil is still scarce. Thus, our objective was to describe the main epidemiological and clinical features of VL/HIV-infected and VL-infected patients in Tocantins.
Albuquerque LCP et al -HIV/AIDS-related visceral leishmaniasis
DIscUssIOn
During the four years of this study (2007) (2008) (2009) (2010) , the signifi cant number of VL cases when compared to the number of VL/HIV cases could have been overestimated because no HIV test was performed preceding the completion of the "LV Investigation Form", which resulted in only 33 patients completing the "HIV infection" fi eld.
Additionally, of the total number of reports for VL infection, 210 records had incomplete "HIV infection" fi elds. This reinforces the importance of fi lling out the form in full, as the information contained in it is extremely important for the planning and execution of surveillance and disease control.
The highest prevalence rate (47.7%) of VL infection in children ≤ 5 years old was reported in other region of Brazil 16, 17 , with similarly high prevalence rates reported in other countries [18] [19] [20] , and it could refl ect increased exposure to sandfl ies 20 . In our study, there were two cases of VL in pregnant patients who transmitted the disease congenitally to their infants 21 . The diagnosis of VL among pregnant women was parasitological due to the presence of Leishmania in the bone marrow aspirate. PCR amplifi cation of parasite kDNA from newborn bone marrow samples suggested that the leishmaniasis was transmitted vertically because the newborns developed signs of the disease shortly after birth 21 .
VL/HIV coinfections were most commonly observed in the age range of 18-50 years (72.7%), and the proportion of male patients was higher in the LV/HIV group (78.8%) than in the VL group (57.5%). . This shows that cases of coinfection have spread throughout Brazil.
Although it has been proposed that VL/HIV coinfections show different clinical manifestations -a lack of visceromegaly or fever, for instance 23, 24 -our study is in accordance with other reports 25, 7 that show that the initial clinical presentation of VL/HIV patients is similar to that of HIV-negative individuals, with fever, splenomegaly and hepatomegaly associated with weakness, weight loss, mucocutaneous pallor, airway infections and/or diarrhea, edema and jaundice. The only difference in symptoms between the two groups was an increased prevalence of infection in HIV-infected patients (25.9% versus 10.7%). However, our study confi rms the fi ndings of previous reports showing that HIV-induced immunosuppression impairs the body's protective mechanisms against intracellular parasites, such as Leishmania species. Additionally, VL could induce intracellular HIV replication, thus speeding up the clinical course of the HIV infection [26] [27] [28] . Consequently, it also demonstrates that VL has emerged as a serious opportunistic infection in HIV-infected patients 29 . Trop 47(1):38-46, Jan-Feb, 2014 The treatment for VL in HIV-infected patients is limited to pentavalent antimonials (sodium stibogluconate (SSG) and meglumine antimoniate) and amphotericin B (AmB, typically in the liposomal formulation AmBisome, Gilead Sciences Inc., Astellas Pharma, North Deerfi eld, IL) 25 . Although the use of pentavalent antimonials is no longer recommended in HIV-infected patients by most experts in the fi eld, due to their unacceptable toxicity and high rates of treatment failure and mortality 30 , we used pentavalent antimonials as the fi rst choice of treatment for VL and VL/HIV infections in our study. In 2005, the World Health Organization stressed the need for multicenter trials of fi rst-line treatment and secondary prophylaxis for patients with VL infected with HIV and the need to include treatment regimens with liposomal amphotericin B
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. Nevertheless, the number of patients who received amphotericin B deoxycholate and liposomal amphotericin B was much higher in the VL/HIV group (31.3%) than in the VL group (11.7%). This indicates that the WHO recommendations for liposomal AmB as the best treatment choice for coinfected patients because of its success rate in the HIV-positive population 2 were followed.
In 2011, the Brazilian Health Ministry (Ministério da Saúde do Brasil) published a new guideline 32 recommending the use of AmB deoxycholate as the fi rst-choice drug in the treatment of VL/HIV coinfection. However, some studies have demonstrated a high frequency of relapses during follow-up 2,33 , further supporting the need for combined therapies.
Furthermore, a VL/HIV-coinfected patient's severely immunocompromised state could hinder the destruction of the parasite and contribute to an increased predisposition to frequent relapses 34 . This tendency toward relapses was observed in our studies (data not shown).
The immune deficiency caused by HIV facilitates the multiplication of the Leishmania parasite and further reduces the rates of cure through conventional treatments 2, 7, 35, 36 . The lethality among the VL/HIV patients in this study was substantially higher than that in the VL patients (data not shown). Generally, infectious complications and bleeding are the main risk factors for death in children with LV. Furthermore, the involvement of the liver in children, which is generally not pronounced and is reversible after treatment, could be quite severe, causing a fatal outcome 37 . Lethality in the VL/HIV group prevailed in individuals older than 40 years, confi rming the observation that adults older than 45 years have a higher risk of dying, possibly due to immune decline at this age. The progression of the disease symptoms with a consequent delay in diagnosis and treatment of patients with VL or VL/HIV has been identifi ed as a risk factor for death 38 . Adverse reactions, including renal and liver failure, cardiac abnormalities and pancreatitis, and hepatitis drugs were also death-precipitating factors. The effi cacy of the therapeutic approach could not be ascertained, and our results are in accordance with other reports 7, 34, 37 . Considering that other opportunistic diseases frequently develop during VL episodes in VL/HIV patients 33 , there was a highly accentuated death rate due to other causes in the VL/HIV group (12.9%) in comparison to the VL group (0.7%). It has been suggested that knowledge regarding the laboratory and clinical profi les of patients and their association with death from VL could assist in clinical management and reduce lethality [39] [40] [41] . Therefore, since 2011, the Brazilian Health Ministry (Ministério da Saúde do Brasil) has recommended the differential diagnosis of opportunistic infections and the use of serological tests for HIV in patients with VL in VL-endemic regions such as Tocantins.
There are some limitations to our study. Although the sample size was large, the number of HIV patients was small, which restricted our multivariate analysis. Because it was only possible to analyze the variables that were included on the notifi cation form (data from the Information System for Notifi able Diseases), other associations could not be ascertained. However, this is the fi rst comparative study on the epidemiologic and clinical features of confi rmed cases of VL and VL/HIV infections in Tocantins, Brazil. Thus, our results contribute to increasing our knowledge of VL and VL/HIV infections, which can be used to implement strategies for the prevention and control of these diseases.
In conclusion, the VL and VL/HIV infections that occur in northern Brazil are comparable to those reported by other studies performed in other endemic areas throughout the world, attesting the fact that VL and VL/HIV infections have been emerging with increased frequency in Brazil. Therefore, there is a distinct need to develop and implement methods to identify new forms of treatment and to improve the diagnostic accuracy and therapeutic management of health services that function to control these diseases.
